-
-
-
-
-
-
-
Regeneron beats first quarter estimates on Dupixent strength
-
-
-
-
-
-
-
Press Release: Sanofi’s lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
-
-
-
-
-
-
-
Press Release: Sanofi's amlitelimab confirms its potential in atopic dermatitis
-
-
-
-
-
-
-
Sanofi's Tzield gets expedited FDA review for stage 3 type 1 diabetes
-
-
-
-
-
-
-
Morgan Stanley Upgrades Sanofi (SNY) to Overweight
-
-
-
-
-
-
-
Sanofi (SNY) to acquire Vigil Neuroscience
-
-
-
-
-
-
-
Sanofi Q1 earnings preview: analysts focus on pipeline, US policy risks
-
1,216,204 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

